Nuvalent
$123.97
19
+$0.47+0.38% 12:32 Today
Statistics
Day High
123.61
Day Low
123.56
52W High
123.69
52W Low
71.13
Volume
25,068
Avg. Volume
-
Mkt Cap
9.78B
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
6AugExpected
Expected EPS
-1.412664
Actual EPS
N/A
Financials
-Profit Margin
Unprofitable0Revenue
-425.38MNet Income
Analyst Ratings
124.00Average Price Target
The highest estimate is 124.00.
From 10 ratings within the last 6 months. This is not an investment recommendation.
From 10 ratings within the last 6 months. This is not an investment recommendation.
Buy 0%
Hold 100%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow NUVL. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Array Technologies
ARRY
Mkt Cap1.1B
AMGEN
AMGN
Mkt Cap193.39B
TG Therapeutics
TGTX
Mkt Cap8.55B
Protagonist Therapeutics
PTGX
Mkt Cap7.69B
Incyte
INCY
Mkt Cap22.73B
Novartis
NVS
Mkt Cap296.54B
Pfizer
PFE
Mkt Cap138.44B
About
Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering novel therapeutic solutions for individuals battling cancer. The company's pipeline features two prominent drug candidates. One of these is NVL-520, a highly selective ROS1 inhibitor capable of penetrating the brain. This compound is specifically designed to target ROS1 fusions that possess the normal ROS1 kinase domain, and crucially, it retains activity against mutations known to confer resistance to both approved and experimental ROS1 inhibitors. NVL-520 is currently undergoing Phase I clinical evaluation. Nuvalent's second key asset is NVL-655, an ALK-selective inhibitor that also exhibits brain-penetrant properties. This therapy seeks to address significant limitations of earlier generations of ALK inhibitors (first-, second-, and third-generation), including the development of treatment resistance, central nervous system-related adverse effects, and brain metastases. NVL-655 is presently being assessed in Phase I/II clinical trials. The company was established in 2017 and is based in Cambridge, Massachusetts.
Show more...
CEO
Dr. James R. Porter Ph.D.
Employees
162
Country
United States
ISIN
US6707031075
Listings
0 Comments
Share your thoughts
FAQ
What is Nuvalent stock price today?▼
The current price of NUVL is $123.97 USD — it has increased by +0.38% in the past 24 hours. Watch Nuvalent stock price performance more closely on the chart.
What is Nuvalent stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Nuvalent stocks are traded under the ticker NUVL.
Is Nuvalent stock price growing?▼
NUVL stock has risen by +0.06% compared to the previous week, the month change is a +35.3% rise, over the last year Nuvalent has showed a +53.54% increase.
What is Nuvalent market cap?▼
Today Nuvalent has the market capitalization of 9.78B
When is the next Nuvalent earnings date?▼
Nuvalent is going to release the next earnings report on August 06, 2026.
What were Nuvalent earnings last quarter?▼
NUVL earnings for the last quarter are -1.39 USD per share, whereas the estimation was -1.34 USD resulting in a -3.72% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Nuvalent revenue for the last year?▼
Nuvalent revenue for the last year amounts to 0 USD.
What is Nuvalent net income for the last year?▼
NUVL net income for the last year is -425.38M USD.
How many employees does Nuvalent have?▼
As of July 02, 2026, the company has 162 employees.
In which sector is Nuvalent located?▼
Nuvalent operates in the Health & Wellness sector.
When did Nuvalent complete a stock split?▼
The last stock split for Nuvalent was on March 10, 2017 with a ratio of 1:1200000.
Where is Nuvalent headquartered?▼
Nuvalent is headquartered in Cambridge, United States.